Abstract: The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.

Abstract: Described are compositions and kits comprising: (i) microorganisms which are able to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora and (ii) microorganisms which are able to inhibit the growth of one or more microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the healthy normal resident skin micro flora, in order to protect the skin against pathogenic microorganisms and to treat skin diseases. The present invention also relates to uses of the above mentioned microorganisms and to methods for the production of compositions and kits comprising such microorganisms.

Abstract: The present invention relates to the use of a microorganism belonging to the group of lactic acid bacteria or a mutant or derivative thereof, characterized in that it is capable of specifically binding to a bacterium belonging to the group of mutans Streptococci, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva, for the preparation of an anticariogenic composition for the treatment or prevention of caries caused by mutans Streptococci other than Streptococcus mutans.

Abstract: Described are microorganisms which are, in a first aspect, able to to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora. In a second aspect microorganisms are described which are able to inhibit the growth of microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the resident skin micro flora. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: The present invention relates to a method for preparing 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof by culturing organisms, in particular yeasts. Furthermore, the invention relates to the preparation of the nucleic acid constructs required for preparing the genetically modified organisms and to said genetically modified organisms, in particular yeasts, themselves.

Abstract: The present invention relates to a method for the production of ergosta-5,7-dienol and/or its biosynthetic intermediates and/or metabolites by culturing genetically modified organisms, and to the genetically modified organisms, in particular yeasts, themselves.

Abstract: Described are microorganisms which are able to inhibit the formation of foot malodor by skin microorganisms. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: Described are microorganisms which are able to suppress the production of malodorous compounds by axillary bacteria. Also described are compositions comprising such microorganisms as well as the use of such micoorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: The invention teaches the use of a tricyclic compound for promoting the endocytotic uptake of macromolecular active ingredients.

Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.

Abstract: The invention concerns new isolated Lactobacillus cells, which are capable to aggregate Helicobacter pylori under culture conditions of the human digestive tract, in particular of the stomach, and to the uses of such cells.

Abstract: The present invention relates to a method for the production of ergosta-5,7-dienol and/or its biosynthetic intermediates and/or metabolites by culturing genetically modified organisms, and to the genetically modified organisms, in particular yeasts, themselves.

Abstract: The present invention relates to a method for preparing 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof by culturing organisms, in particular yeasts. Furthermore, the invention relates to the preparation of the nucleic acid constructs required for preparing the genetically modified organisms and to said genetically modified organisms, in particular yeasts, themselves.

Abstract: The present invention relates to a method for preparing zymosterol and/or the biosynthetic intermediates and/or secondary products thereof by culturing organisms, in particular yeasts, which, compared to the wild type, have an increased lanosterol-C14-demethylase activity and increased HMG-CoA-reductase activity, to the nucleic acid constructs required for preparing the genetically modified organisms and to the genetically modified organisms themselves, in particular yeasts.

Abstract: A process for the production of ergosterol and its intermediate products using recombinant yeasts and plasmids for transformation of yeasts is described.

Abstract: The invention relates to the use of polygalacturonides as food additives, said polygalacturonides being obtainable via the following process steps:

Abstract: The invention relates to a screening method for discovering auxiliary agents promoting endocytosis of low molecular and/or macro-molecular compounds, especially nucleic acids, in cells, comprising the following steps: a) a yeast strain is selected and yeast cells are cultivated therefrom, b) the yeast cells are incubated with a potential auxiliary agent promoting the endocytosis of low molecular and/or macro-molecular compounds, especially nucleic acids, in cells in addition to a nucleic acid which is replicable and/or replicable in the nucleus and/or in the cytosol of the yeast cells or a low and/or macro-molecular compound, c) the transformation rates or the transport rates into the cytosol or the nucleus are determined and analysis occurs if the transformation rates or transport rates increase in comparison with the transformation rates or transport rates in a reference test in which the auxiliary substance is not used, d) the auxiliary substance is selected or rejected according to the result of the value

Abstract: The invention relates to the use of polygalacturonides as food additives, said polygalacturonides being obtainable via the following process steps: a) a pectinous plant material is subjected to a pectin extraction in aqueous solution; b) the solids are removed from the suspension obtained in step a), consisting of liquid phase including dissolved pectin and solids from the plant material; c) the pectin is precipitated from the liquid phase obtained in step b); d) the pectin obtained in step c) is dissolved in an aqueous solution and cleaved with purified endo-polygalacturonase; e) the polygalacturonides obtained in step d) are processed into a polygalacturonide preparation without using an additional separation step and without hydrolyzing ester groups that are present.

Abstract: The invention relates to the use of polygalacturonides as food additives, said polygalacturonides being obtainable via the following process steps: